The seroprevalence of hepatitis A in Istanbul, Turkey

Basit Öğe Kaydı
dc.authorid0000-0002-7210-1084en_US
dc.authorid0000-0003-3799-1090en_US
dc.authorid0000-0001-5278-0174en_US
dc.contributor.authorKaradeniz, Asli
dc.contributor.authorAkduman Alasehir, Elcin
dc.contributor.authorYesilbag, Zuhal
dc.contributor.authorBalikci, Ahmet
dc.contributor.authorYaman, Gorkem
dc.date.accessioned2024-07-12T21:51:48Z
dc.date.available2024-07-12T21:51:48Z
dc.date.issued2017en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractObjective: Hepatitis A, a leading cause of enterically transmitted acute viral hepatitis throughout the world, has changed its pattern in developing countries. The objective of this study is to determine the current seroprevalence of hepatitis A virus (HAV) for different age groups in Istanbul, Turkey. Materials and Methods: Serum samples of 3,868 patients, which had been previously taken, were used to determine anti-HAV IgG levels by the microparticle enzyme immunoassay (MPEIA) method (Architect SR i1000 and i2000, Abbott Diagnostics, Germany) between January 2011 and December 2013. Results: The prevalence of total anti-HAV antibodies was 64.8% for all patients. Among the 3,868 serum samples tested, 54% were from male patients and 46 % were from female patients. Seropositivity rates among the age groups were determined and anti-HAV antibody positivity rates were 55% for the 0-16 age group; 47% for the 17-30 age group; 73.5% for the 31-45 age group and the seroprevalence increased significantly from 50% (972/1944) in 0 to 30 years old to 89% in patients older than 46 years. Conclusion: The low seronegativity rates in young adults, show this group to be at high risk of acquiring an HAV infection. The results support the routine vaccination of children and the seronegative young adults against HAV.en_US
dc.identifier.doi10.5472/marumj.299380
dc.identifier.endpage17en_US
dc.identifier.issn1309-9469
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85032665123en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage14en_US
dc.identifier.urihttps://dx.doi.org/10.5472/marumj.299380
dc.identifier.urihttps://hdl.handle.net/20.500.12415/8318
dc.identifier.volume30en_US
dc.identifier.wosWOS:000430070100003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherMARMARA UNIV, FAC MEDICINEen_US
dc.relation.ispartofMARMARA MEDICAL JOURNALen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY02827
dc.subjectHepatitis A virusen_US
dc.subjectSeroprevalenceen_US
dc.subjectHepatitis A vaccineen_US
dc.titleThe seroprevalence of hepatitis A in Istanbul, Turkeyen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu